EyePoint Pharmaceuticals, Inc.a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that the first patient has been dosed in the Phase 2 "Durasert
Found this useful? Share it with your team.
